CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) - USD ($)
|
Total |
Preferred Stock
Series B Convertible Preferred Stock
|
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
| Beginning Balance at Dec. 31, 2019 |
$ (24,078,857)
|
$ 13
|
$ 344,029
|
$ 31,259,365
|
$ (55,682,264)
|
| Beginning Balance, Shares at Dec. 31, 2019 |
|
13,000
|
34,402,943
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
25,614
|
|
|
25,614
|
|
| Exercise of stock options |
71,596
|
|
$ 8,177
|
63,419
|
|
| Exercise of stock options, Shares |
|
|
817,732
|
|
|
| Net Income/(Loss) |
5,438,024
|
|
|
|
5,438,024
|
| Ending Balance at Mar. 31, 2020 |
(18,543,623)
|
$ 13
|
$ 352,206
|
31,348,398
|
(50,244,240)
|
| Ending Balance, Shares at Mar. 31, 2020 |
|
13,000
|
35,220,675
|
|
|
| Beginning Balance at Dec. 31, 2019 |
(24,078,857)
|
$ 13
|
$ 344,029
|
31,259,365
|
(55,682,264)
|
| Beginning Balance, Shares at Dec. 31, 2019 |
|
13,000
|
34,402,943
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
189,938
|
|
|
|
|
| Net Income/(Loss) |
(3,401,075)
|
|
|
|
|
| Ending Balance at Sep. 30, 2020 |
(21,721,521)
|
$ 13
|
$ 358,499
|
37,003,306
|
(59,083,339)
|
| Ending Balance, Shares at Sep. 30, 2020 |
|
13,000
|
35,849,961
|
|
|
| Beginning Balance at Mar. 31, 2020 |
(18,543,623)
|
$ 13
|
$ 352,206
|
31,348,398
|
(50,244,240)
|
| Beginning Balance, Shares at Mar. 31, 2020 |
|
13,000
|
35,220,675
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
155,186
|
|
|
155,186
|
|
| Exercise of stock options |
19,200
|
|
$ 6,293
|
12,907
|
|
| Exercise of stock options, Shares |
|
|
629,286
|
|
|
| Option grants for investment in subsidiaries |
5,477,677
|
|
|
5,477,677
|
|
| Net Income/(Loss) |
(3,411,517)
|
|
|
|
(3,411,517)
|
| Ending Balance at Jun. 30, 2020 |
(16,303,077)
|
$ 13
|
$ 358,499
|
36,994,168
|
(53,655,757)
|
| Ending Balance, Shares at Jun. 30, 2020 |
|
13,000
|
35,849,961
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
9,138
|
|
|
9,138
|
|
| Net Income/(Loss) |
(5,427,582)
|
|
|
|
(5,427,582)
|
| Ending Balance at Sep. 30, 2020 |
(21,721,521)
|
$ 13
|
$ 358,499
|
37,003,306
|
(59,083,339)
|
| Ending Balance, Shares at Sep. 30, 2020 |
|
13,000
|
35,849,961
|
|
|
| Beginning Balance at Dec. 31, 2020 |
(28,734,073)
|
$ 13
|
$ 358,499
|
37,139,854
|
(66,232,439)
|
| Beginning Balance, Shares at Dec. 31, 2020 |
|
13,000
|
35,850,089
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
102,000
|
|
|
102,000
|
|
| Shares issued upon reverse split to avoid fractional shares |
|
|
$ 19
|
(19)
|
|
| Shares issued upon reverse split to avoid fractional shares, Shares |
|
|
1,793
|
|
|
| Conversion of note payable to shares |
476,036
|
|
$ 15,868
|
460,168
|
|
| Conversion of note payable to shares, Shares |
|
|
1,586,786
|
|
|
| Net Income/(Loss) |
(8,221,174)
|
|
|
|
(8,221,174)
|
| Ending Balance at Mar. 31, 2021 |
(36,377,211)
|
$ 13
|
$ 374,386
|
37,702,003
|
(74,453,613)
|
| Ending Balance, Shares at Mar. 31, 2021 |
|
13,000
|
37,438,668
|
|
|
| Beginning Balance at Dec. 31, 2020 |
(28,734,073)
|
$ 13
|
$ 358,499
|
37,139,854
|
(66,232,439)
|
| Beginning Balance, Shares at Dec. 31, 2020 |
|
13,000
|
35,850,089
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
450,320
|
|
|
|
|
| Purchase of Agribody Technologies, Inc |
$ 5,000,000
|
|
|
|
|
| Purchase of Agribody Technologies, Inc, Shares |
830,526
|
|
|
|
|
| Net Income/(Loss) |
$ (33,980,426)
|
|
|
|
|
| Ending Balance at Sep. 30, 2021 |
(53,368,415)
|
$ 0
|
$ 400,630
|
46,443,820
|
(100,212,865)
|
| Ending Balance, Shares at Sep. 30, 2021 |
|
0
|
40,063,068
|
|
|
| Beginning Balance at Mar. 31, 2021 |
(36,377,211)
|
$ 13
|
$ 374,386
|
37,702,003
|
(74,453,613)
|
| Beginning Balance, Shares at Mar. 31, 2021 |
|
13,000
|
37,438,668
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
154,244
|
|
|
154,244
|
|
| Exercise of stock options |
9,344
|
|
$ 610
|
8,734
|
|
| Exercise of stock options, Shares |
|
|
60,978
|
|
|
| Purchase of Agribody Technologies, Inc |
5,000,000
|
|
$ 8,305
|
4,991,695
|
|
| Purchase of Agribody Technologies, Inc, Shares |
|
|
830,526
|
|
|
| Conversion of Series B Preferred to Common, Shares |
|
(13,000)
|
1,181,819
|
|
|
| Conversion of Series B Preferred to Common |
|
$ (13)
|
$ 11,818
|
(11,805)
|
|
| Conversion of convertible notes, Shares |
|
|
53,723
|
|
|
| Conversion of convertible notes |
308,889
|
|
$ 537
|
308,352
|
|
| Issuance of common stock for cash |
3,100,000
|
|
$ 4,960
|
3,095,040
|
|
| Issuance of common stock for cash, Shares |
|
|
496,000
|
|
|
| Net Income/(Loss) |
(14,078,302)
|
|
|
|
(14,078,302)
|
| Ending Balance at Jun. 30, 2021 |
(41,883,036)
|
$ 0
|
$ 400,616
|
46,248,263
|
(88,531,915)
|
| Ending Balance, Shares at Jun. 30, 2021 |
|
0
|
40,061,714
|
|
|
| Share-based compensation from issuance of options and compensation-based warrants |
194,076
|
|
|
194,076
|
|
| Exercise of stock options |
1,495
|
|
$ 14
|
1,481
|
|
| Exercise of stock options, Shares |
|
|
1,354
|
|
|
| Net Income/(Loss) |
(11,680,950)
|
|
|
|
(11,680,950)
|
| Ending Balance at Sep. 30, 2021 |
$ (53,368,415)
|
$ 0
|
$ 400,630
|
$ 46,443,820
|
$ (100,212,865)
|
| Ending Balance, Shares at Sep. 30, 2021 |
|
0
|
40,063,068
|
|
|